Work

Supplementary Table S2 from A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

Year: 2023

Type: supplementary-materials

Abstract: Plasma concentrations of abemaciclib after a single dose (C1D1) or at steady state, following a twice-daily dosing schedule of abemaciclib.

DOI: 10.1158/1078-0432.22477395

Authors: Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361888808

Cites:

Cited by:

Related to: 10